

**Sexually  
Transmitted  
Disease  
Surveillance  
2023:  
Enhanced Gonococcal Isolate  
Surveillance Project  
Site-Specific Profiles**

**Division of STD Prevention  
August 2025**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE CONTROL AND PREVENTION  
NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STD, AND TB PREVENTION  
DIVISION OF STD PREVENTION  
ATLANTA, GEORGIA 30329-4027**

## Acknowledgments

2

Publication of this report would not have been possible without the contributions of all participating state and local health departments, sexually transmitted disease clinics, public health laboratories, and regional laboratories.

This report was prepared by:

Sammie Haskin, Alesia Harvey, Rebekah Frankson, Kristen Kreisel, Emily Rowlinson, and Luke Shouse, Surveillance and Data Science Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Additional contributions by Matthew Schmerer, Myriam Bèlanger, and Ellen Kersh, STD Laboratory Reference and Research Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, and LaShondra Berman and Eboni Galloway, Behavioral Science and Epidemiology Branch of the Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

## Copyright Information

All material contained in this report is in the public domain and may be used and reprinted without special permission; however, citation as to source is appreciated.

## Suggested Citation

Centers for Disease Control and Prevention. *Sexually Transmitted Disease Surveillance 2023: Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles*. Atlanta: U.S. Department of Health and Human Services; 2025.

## Web Site

The online version of this report is available at <https://www.cdc.gov/sti-statistics/qisp-profiles/>.

## Technical Note

Antimicrobial susceptibility data presented in this report are based on criteria established by the Clinical & Laboratory Standards Institute (CLSI) and the FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria (FDA-STIC).

**2023 Enhanced Gonococcal Isolate Surveillance Project**  
**Clinical Sites and Years Participated**

Columbus, Ohio (2018-2019, 2023)	Orange County, California (2018–2023)
Honolulu, Hawaii (2023)	Philadelphia, Pennsylvania (2018–2023)
Las Vegas, Nevada (2018–2023)	Phoenix, Arizona (2020–2023)
Minneapolis, Minnesota (2018–2019, 2023)	Pontiac, Michigan (2018–2023)
New Orleans, Louisiana (2018–2023)	San Diego, California (2018–2023)

**2023 Enhanced Gonococcal Isolate Surveillance Project Regional Laboratories**

Maryland Department of Health and Mental Hygiene <i>Baltimore, Maryland</i>
Tennessee Department of Health <i>Nashville, Tennessee</i>
Utah Department of Health <i>Salt Lake City, Utah</i>
Washington State Department of Health <i>Seattle, Washington</i>

**2023 Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles**  
**Table of Contents**

<a href="#">Columbus, Ohio</a> .....	6-10
<a href="#">Honolulu, Hawaii</a> .....	11-15
<a href="#">Las Vegas, Nevada</a> .....	16-23
<a href="#">Minneapolis, Minnesota</a> .....	24-28
<a href="#">New Orleans, Louisiana</a> .....	29-36
<a href="#">Orange County, California</a> .....	37-44
<a href="#">Philadelphia, Pennsylvania</a> .....	45-52
<a href="#">Phoenix, Arizona</a> .....	53-60
<a href="#">Pontiac, Michigan</a> .....	61-68
<a href="#">San Diego, California</a> .....	69-76

**2023 Enhanced Gonococcal Isolate Surveillance Project Site-Specific Profiles**  
**List of Tables**

For each participating site of the 2023 Gonococcal Isolate Surveillance Project, the following tables are presented:

Table A.	Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2023
Table B.	Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2023
Table C.	Number of <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021–2023
Table D.	Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021–2023
Table E.	Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021–2023
Table F.	Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among <i>Neisseria gonorrhoeae</i> Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021–2023
Table G.	Percentage of <i>Neisseria gonorrhoeae</i> Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021–2023
Table H.	Percentage of <i>Neisseria gonorrhoeae</i> Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021–2023
Table I.	Percentage of <i>Neisseria gonorrhoeae</i> Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021–2023
Table J.	Percentage of <i>Neisseria gonorrhoeae</i> Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), 2021–2023

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	2 (4.4)	9 (20.0)	12 (26.7)	11 (24.4)	1 (2.2)	5 (11.1)	2 (4.4)	0 (0)	0 (0)	2 (4.4)	1 (2.2)	45
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	0 (0)	36 (80.0)	1 (2.2)	3 (6.7)	4 (8.9)	1 (2.2)	0 (0)	45
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	9	36	0	45
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0	0	0	0
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0	0	0	0

MSM = Men who have sex with men; MSW = Men who have sex with women only.

\* Site did not participate in eGISP during that year.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	40 (88.9)	4 (8.9)	0 (0.0)	1 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	45
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	39 (86.7)	6 (13.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	45
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint. As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	9 (20.0)	29 (64.4)	2 (4.4)	4 (8.9)	0 (0.0)	0 (0.0)	1 (2.2)	0 (0.0)	45
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.



Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 9 (0.0)	0 / 36 (0.0)	0 / 0 (0.0)	0 / 45 (0.0)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 9 (0.0)	0 / 36 (0.0)	0 / 0 (0.0)	0 / 45 (0.0)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 9 (0.0)	1 / 36 (2.8)	0 / 0 (0.0)	1 / 45 (2.2)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Columbus, Ohio, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	0 (0)	5 (20.8)	3 (12.5)	3 (12.5)	4 (16.7)	3 (12.5)	0 (0)	1 (4.2)	2 (8.3)	0 (0)	3 (12.5)	24
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	1 (50.0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	5 (20.8)	4 (16.7)	2 (8.3)	9 (37.5)	0 (0)	4 (16.7)	0 (0)	24
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	1 (50.0)	1 (50.0)	0 (0)	0 (0)	0 (0)	2
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	11	11	0	22
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	2	0	0	2
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0	0	0	0

MSM = Men who have sex with men; MSW = Men who have sex with women only.

\* Site did not participate in eGISP during that year.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	15 (62.5)	4 (16.7)	1 (4.2)	1 (4.2)	2 (8.3)	0 (0.0)	0 (0.0)	1 (4.2)	24
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	14 (58.3)	6 (25.0)	1 (4.2)	2 (8.3)	0 (0.0)	1 (4.2)	0 (0.0)	0 (0.0)	24
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint. As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	6 (25.0)	7 (29.2)	4 (16.7)	7 (29.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	24
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	1 (50.0)	0 (0.0)	0 (0.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 11 (0.0)	3 / 11 (27.3)	0 / 0 (0.0)	3 / 22 (13.6)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 11 (0.0)	1 / 11 (9.1)	0 / 0 (0.0)	1 / 22 (4.5)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 11 (0.0)	0 / 11 (0.0)	0 / 0 (0.0)	0 / 22 (0.0)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Honolulu, Hawaii, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	6 / 11 (54.5)	8 / 11 (72.7)	0 / 0 (0.0)	14 / 22 (63.6)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	2 / 2 (100.0)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 2 (100.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	18 (12.5)	27 (18.8)	29 (20.1)	27 (18.8)	15 (10.4)	12 (8.3)	8 (5.6)	2 (1.4)	3 (2.1)	1 (0.7)	2 (1.4)	144
Genital	Female	2 (40.0)	1 (20.0)	0 (0)	0 (0)	1 (20.0)	0 (0)	0 (0)	1 (20.0)	0 (0)	0 (0)	0 (0)	5
Pharyngeal	Male	0 (0)	5 (16.7)	8 (26.7)	4 (13.3)	3 (10.0)	4 (13.3)	3 (10.0)	1 (3.3)	0 (0)	1 (3.3)	1 (3.3)	30
Pharyngeal	Female	3 (42.9)	1 (14.3)	2 (28.6)	1 (14.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	7
Rectal	Male	1 (3.3)	4 (13.3)	8 (26.7)	10 (33.3)	2 (6.7)	3 (10.0)	1 (3.3)	0 (0)	1 (3.3)	0 (0)	0 (0)	30
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	2 (1.4)	3 (2.1)	51 (35.4)	0 (0)	35 (24.3)	42 (29.2)	3 (2.1)	8 (5.6)	144
Genital	Female	0 (0)	1 (20.0)	1 (20.0)	0 (0)	1 (20.0)	2 (40.0)	0 (0)	0 (0)	5
Pharyngeal	Male	0 (0)	0 (0)	6 (20.0)	0 (0)	12 (40.0)	10 (33.3)	2 (6.7)	0 (0)	30
Pharyngeal	Female	0 (0)	0 (0)	4 (57.1)	0 (0)	1 (14.3)	2 (28.6)	0 (0)	0 (0)	7
Rectal	Male	0 (0)	2 (6.7)	2 (6.7)	1 (3.3)	11 (36.7)	13 (43.3)	1 (3.3)	0 (0)	30
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.



Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	48	117	1	166
Genital	2022	47	129	0	176
Genital	2023	53	90	4	147
Pharyngeal	2021	10	7	4	21
Pharyngeal	2022	14	9	2	25
Pharyngeal	2023	20	10	7	37
Rectal	2021	10	0	0	10
Rectal	2022	21	0	1	22
Rectal	2023	29	0	0	29

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	118 (70.2)	34 (20.2)	8 (4.8)	7 (4.2)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	168
Genital	2022	116 (65.5)	49 (27.7)	5 (2.8)	7 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	177
Genital	2023	94 (63.1)	27 (18.1)	10 (6.7)	18 (12.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	149
Pharyngeal	2021	7 (31.8)	10 (45.5)	3 (13.6)	2 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22
Pharyngeal	2022	12 (48.0)	8 (32.0)	3 (12.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25
Pharyngeal	2023	22 (59.5)	6 (16.2)	4 (10.8)	4 (10.8)	1 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	37
Rectal	2021	5 (45.5)	5 (45.5)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	15 (65.2)	7 (30.4)	0 (0.0)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23
Rectal	2023	21 (70.0)	3 (10.0)	4 (13.3)	2 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	93 (55.4)	60 (35.7)	13 (7.7)	2 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	168
Genital	2022	120 (67.8)	54 (30.5)	3 (1.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	177
Genital	2023	76 (51.0)	48 (32.2)	25 (16.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	149
Pharyngeal	2021	8 (36.4)	10 (45.5)	4 (18.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22
Pharyngeal	2022	17 (68.0)	6 (24.0)	2 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	25
Pharyngeal	2023	17 (45.9)	14 (37.8)	6 (16.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	37
Rectal	2021	5 (45.5)	2 (18.2)	4 (36.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	17 (73.9)	5 (21.7)	1 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23
Rectal	2023	15 (50.0)	10 (33.3)	5 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	26 (15.5)	103 (61.3)	14 (8.3)	14 (8.3)	11 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	168
Genital	2022	38 (21.5)	88 (49.7)	19 (10.7)	30 (16.9)	1 (0.6)	0 (0.0)	1 (0.6)	0 (0.0)	177
Genital	2023	17 (11.4)	84 (56.4)	16 (10.7)	22 (14.8)	10 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	149
Pharyngeal	2021	2 (9.1)	15 (68.2)	3 (13.6)	2 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	22
Pharyngeal	2022	4 (16.0)	8 (32.0)	3 (12.0)	9 (36.0)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	25
Pharyngeal	2023	5 (13.5)	16 (43.2)	7 (18.9)	6 (16.2)	3 (8.1)	0 (0.0)	0 (0.0)	0 (0.0)	37
Rectal	2021	2 (18.2)	6 (54.5)	0 (0.0)	0 (0.0)	3 (27.3)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	1 (4.3)	11 (47.8)	5 (21.7)	6 (26.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	23
Rectal	2023	2 (6.7)	14 (46.7)	9 (30.0)	4 (13.3)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	30

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 48 (0.0)	1 / 117 (0.9)	0 / 1 (0.0)	1 / 166 (0.6)
Genital	2022	0 / 47 (0.0)	0 / 129 (0.0)	0 / 0 (0.0)	0 / 176 (0.0)
Genital	2023	0 / 53 (0.0)	0 / 90 (0.0)	0 / 4 (0.0)	0 / 147 (0.0)
Pharyngeal	2021	0 / 10 (0.0)	0 / 7 (0.0)	0 / 4 (0.0)	0 / 21 (0.0)
Pharyngeal	2022	0 / 14 (0.0)	0 / 9 (0.0)	0 / 2 (0.0)	0 / 25 (0.0)
Pharyngeal	2023	1 / 20 (5.0)	0 / 10 (0.0)	0 / 7 (0.0)	1 / 37 (2.7)
Rectal	2021	0 / 10 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 10 (0.0)
Rectal	2022	0 / 21 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 22 (0.0)
Rectal	2023	0 / 29 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 29 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 48 (0.0)	0 / 117 (0.0)	0 / 1 (0.0)	0 / 166 (0.0)
Genital	2022	0 / 47 (0.0)	0 / 129 (0.0)	0 / 0 (0.0)	0 / 176 (0.0)
Genital	2023	0 / 53 (0.0)	0 / 90 (0.0)	0 / 4 (0.0)	0 / 147 (0.0)
Pharyngeal	2021	0 / 10 (0.0)	0 / 7 (0.0)	0 / 4 (0.0)	0 / 21 (0.0)
Pharyngeal	2022	0 / 14 (0.0)	0 / 9 (0.0)	0 / 2 (0.0)	0 / 25 (0.0)
Pharyngeal	2023	0 / 20 (0.0)	0 / 10 (0.0)	0 / 7 (0.0)	0 / 37 (0.0)
Rectal	2021	0 / 10 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 10 (0.0)
Rectal	2022	0 / 21 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 22 (0.0)
Rectal	2023	0 / 29 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 29 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	7 / 48 (14.6)	4 / 117 (3.4)	0 / 1 (0.0)	11 / 166 (6.6)
Genital	2022	1 / 47 (2.1)	1 / 129 (0.8)	0 / 0 (0.0)	2 / 176 (1.1)
Genital	2023	3 / 53 (5.7)	7 / 90 (7.8)	0 / 4 (0.0)	10 / 147 (6.8)
Pharyngeal	2021	0 / 10 (0.0)	0 / 7 (0.0)	0 / 4 (0.0)	0 / 21 (0.0)
Pharyngeal	2022	1 / 14 (7.1)	0 / 9 (0.0)	0 / 2 (0.0)	1 / 25 (4.0)
Pharyngeal	2023	2 / 20 (10.0)	0 / 10 (0.0)	1 / 7 (14.3)	3 / 37 (8.1)
Rectal	2021	3 / 10 (30.0)	0 / 0 (0.0)	0 / 0 (0.0)	3 / 10 (30.0)
Rectal	2022	0 / 21 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 22 (0.0)
Rectal	2023	1 / 29 (3.4)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 29 (3.4)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Las Vegas, Nevada, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	18 / 48 (37.5)	40 / 117 (34.2)	1 / 1 (100.0)	59 / 166 (35.5)
Genital	2022	22 / 47 (46.8)	28 / 129 (21.7)	0 / 0 (0.0)	50 / 176 (28.4)
Genital	2023	29 / 53 (54.7)	25 / 90 (27.8)	2 / 4 (50.0)	56 / 147 (38.1)
Pharyngeal	2021	5 / 10 (50.0)	2 / 7 (28.6)	1 / 4 (25.0)	8 / 21 (38.1)
Pharyngeal	2022	8 / 14 (57.1)	0 / 9 (0.0)	1 / 2 (50.0)	9 / 25 (36.0)
Pharyngeal	2023	10 / 20 (50.0)	2 / 10 (20.0)	3 / 7 (42.9)	15 / 37 (40.5)
Rectal	2021	4 / 10 (40.0)	0 / 0 (0.0)	0 / 0 (0.0)	4 / 10 (40.0)
Rectal	2022	4 / 21 (19.0)	0 / 0 (0.0)	1 / 1 (100.0)	5 / 22 (22.7)
Rectal	2023	11 / 29 (37.9)	0 / 0 (0.0)	0 / 0 (0.0)	11 / 29 (37.9)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	2 (4.1)	4 (8.2)	12 (24.5)	12 (24.5)	9 (18.4)	2 (4.1)	3 (6.1)	3 (6.1)	0 (0)	1 (2.0)	1 (2.0)	49
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	1 (2.0)	0 (0)	28 (57.1)	1 (2.0)	11 (22.4)	3 (6.1)	2 (4.1)	3 (6.1)	49
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.



Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	16	30	0	46
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0	0	0	0
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0	0	0	0

MSM = Men who have sex with men; MSW = Men who have sex with women only.

\* Site did not participate in eGISP during that year.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	40 (81.6)	7 (14.3)	1 (2.0)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	49
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	41 (83.7)	6 (12.2)	1 (2.0)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	49
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	*	*	*	*	*	*	*	*	*
Genital	2022	*	*	*	*	*	*	*	*	*
Genital	2023	7 (14.3)	35 (71.4)	2 (4.1)	5 (10.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	49
Pharyngeal	2021	*	*	*	*	*	*	*	*	*
Pharyngeal	2022	*	*	*	*	*	*	*	*	*
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	*	*	*	*	*	*	*	*	*
Rectal	2022	*	*	*	*	*	*	*	*	*
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 16 (0.0)	0 / 30 (0.0)	0 / 0 (0.0)	0 / 46 (0.0)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 16 (0.0)	0 / 30 (0.0)	0 / 0 (0.0)	0 / 46 (0.0)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	0 / 16 (0.0)	0 / 30 (0.0)	0 / 0 (0.0)	0 / 46 (0.0)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Minneapolis, Minnesota, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	*	*	*	*
Genital	2022	*	*	*	*
Genital	2023	6 / 16 (37.5)	5 / 30 (16.7)	0 / 0 (0.0)	11 / 46 (23.9)
Pharyngeal	2021	*	*	*	*
Pharyngeal	2022	*	*	*	*
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	*	*	*	*
Rectal	2022	*	*	*	*
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

\* Site did not participate in eGISP during that year.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	1 (1.2)	19 (22.6)	16 (19.0)	13 (15.5)	16 (19.0)	8 (9.5)	5 (6.0)	3 (3.6)	1 (1.2)	2 (2.4)	0 (0)	84
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	5 (35.7)	3 (21.4)	5 (35.7)	1 (7.1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	14
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	1 (50.0)	1 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	1 (1.2)	2 (2.4)	43 (51.2)	0 (0)	30 (35.7)	6 (7.1)	1 (1.2)	1 (1.2)	84
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	7 (50.0)	0 (0)	7 (50.0)	0 (0)	0 (0)	0 (0)	14
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	2 (100.0)	0 (0)	0 (0)	0 (0)	2
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	41	33	1	75
Genital	2022	42	24	0	66
Genital	2023	57	27	0	84
Pharyngeal	2021	13	1	1	15
Pharyngeal	2022	7	3	0	10
Pharyngeal	2023	14	0	0	14
Rectal	2021	3	1	0	4
Rectal	2022	9	0	0	9
Rectal	2023	2	0	0	2

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	57 (74.0)	13 (16.9)	6 (7.8)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	77
Genital	2022	48 (68.6)	12 (17.1)	6 (8.6)	4 (5.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Genital	2023	50 (59.5)	14 (16.7)	2 (2.4)	17 (20.2)	1 (1.2)	0 (0.0)	0 (0.0)	0 (0.0)	84
Pharyngeal	2021	13 (86.7)	1 (6.7)	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Pharyngeal	2022	8 (80.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Pharyngeal	2023	9 (64.3)	0 (0.0)	1 (7.1)	4 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2021	3 (75.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	6 (60.0)	4 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2023	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	59 (76.6)	16 (20.8)	1 (1.3)	1 (1.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	77
Genital	2022	43 (61.4)	25 (35.7)	2 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Genital	2023	54 (64.3)	21 (25.0)	9 (10.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	84
Pharyngeal	2021	11 (73.3)	4 (26.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	15
Pharyngeal	2022	7 (70.0)	3 (30.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Pharyngeal	2023	6 (42.9)	5 (35.7)	3 (21.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2021	3 (75.0)	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	6 (60.0)	3 (30.0)	1 (10.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	10
Rectal	2023	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	5 (6.5)	42 (54.5)	12 (15.6)	9 (11.7)	9 (11.7)	0 (0.0)	0 (0.0)	0 (0.0)	77
Genital	2022	13 (18.6)	31 (44.3)	13 (18.6)	8 (11.4)	4 (5.7)	1 (1.4)	0 (0.0)	0 (0.0)	70
Genital	2023	15 (17.9)	47 (56.0)	8 (9.5)	8 (9.5)	6 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	84
Pharyngeal	2021	1 (6.7)	8 (53.3)	1 (6.7)	4 (26.7)	1 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	15
Pharyngeal	2022	3 (30.0)	3 (30.0)	0 (0.0)	2 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (20.0)	10
Pharyngeal	2023	1 (7.1)	5 (35.7)	2 (14.3)	4 (28.6)	1 (7.1)	0 (0.0)	0 (0.0)	1 (7.1)	14
Rectal	2021	0 (0.0)	2 (50.0)	0 (0.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Rectal	2022	1 (10.0)	4 (40.0)	1 (10.0)	1 (10.0)	1 (10.0)	0 (0.0)	0 (0.0)	2 (20.0)	10
Rectal	2023	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.



Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	1 / 41 (2.4)	0 / 33 (0.0)	0 / 1 (0.0)	1 / 75 (1.3)
Genital	2022	0 / 42 (0.0)	0 / 24 (0.0)	0 / 0 (0.0)	0 / 66 (0.0)
Genital	2023	1 / 57 (1.8)	0 / 27 (0.0)	0 / 0 (0.0)	1 / 84 (1.2)
Pharyngeal	2021	0 / 13 (0.0)	0 / 1 (0.0)	0 / 1 (0.0)	0 / 15 (0.0)
Pharyngeal	2022	0 / 7 (0.0)	0 / 3 (0.0)	0 / 0 (0.0)	0 / 10 (0.0)
Pharyngeal	2023	0 / 14 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 14 (0.0)
Rectal	2021	0 / 3 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Rectal	2022	0 / 9 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 9 (0.0)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 41 (0.0)	0 / 33 (0.0)	0 / 1 (0.0)	0 / 75 (0.0)
Genital	2022	0 / 42 (0.0)	0 / 24 (0.0)	0 / 0 (0.0)	0 / 66 (0.0)
Genital	2023	0 / 57 (0.0)	0 / 27 (0.0)	0 / 0 (0.0)	0 / 84 (0.0)
Pharyngeal	2021	0 / 13 (0.0)	0 / 1 (0.0)	0 / 1 (0.0)	0 / 15 (0.0)
Pharyngeal	2022	0 / 7 (0.0)	0 / 3 (0.0)	0 / 0 (0.0)	0 / 10 (0.0)
Pharyngeal	2023	0 / 14 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 14 (0.0)
Rectal	2021	0 / 3 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Rectal	2022	0 / 9 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 9 (0.0)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	6 / 41 (14.6)	2 / 33 (6.1)	0 / 1 (0.0)	8 / 75 (10.7)
Genital	2022	4 / 42 (9.5)	1 / 24 (4.2)	0 / 0 (0.0)	5 / 66 (7.6)
Genital	2023	6 / 57 (10.5)	0 / 27 (0.0)	0 / 0 (0.0)	6 / 84 (7.1)
Pharyngeal	2021	0 / 13 (0.0)	1 / 1 (100.0)	0 / 1 (0.0)	1 / 15 (6.7)
Pharyngeal	2022	2 / 7 (28.6)	0 / 3 (0.0)	0 / 0 (0.0)	2 / 10 (20.0)
Pharyngeal	2023	2 / 14 (14.3)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 14 (14.3)
Rectal	2021	0 / 3 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Rectal	2022	3 / 9 (33.3)	0 / 0 (0.0)	0 / 0 (0.0)	3 / 9 (33.3)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), New Orleans, Louisiana, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	11 / 41 (26.8)	15 / 33 (45.5)	1 / 1 (100.0)	27 / 75 (36.0)
Genital	2022	14 / 42 (33.3)	10 / 24 (41.7)	0 / 0 (0.0)	24 / 66 (36.4)
Genital	2023	24 / 57 (42.1)	12 / 27 (44.4)	0 / 0 (0.0)	36 / 84 (42.9)
Pharyngeal	2021	4 / 13 (30.8)	0 / 1 (0.0)	0 / 1 (0.0)	4 / 15 (26.7)
Pharyngeal	2022	4 / 7 (57.1)	0 / 3 (0.0)	0 / 0 (0.0)	4 / 10 (40.0)
Pharyngeal	2023	9 / 14 (64.3)	0 / 0 (0.0)	0 / 0 (0.0)	9 / 14 (64.3)
Rectal	2021	1 / 3 (33.3)	1 / 1 (100.0)	0 / 0 (0.0)	2 / 4 (50.0)
Rectal	2022	4 / 9 (44.4)	0 / 0 (0.0)	0 / 0 (0.0)	4 / 9 (44.4)
Rectal	2023	1 / 2 (50.0)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 2 (50.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	1 (0.8)	11 (8.6)	31 (24.2)	26 (20.3)	15 (11.7)	20 (15.6)	9 (7.0)	2 (1.6)	7 (5.5)	4 (3.1)	2 (1.6)	128
Genital	Female	1 (16.7)	1 (16.7)	0 (0)	0 (0)	0 (0)	0 (0)	3 (50.0)	1 (16.7)	0 (0)	0 (0)	0 (0)	6
Pharyngeal	Male	2 (2.6)	11 (14.5)	14 (18.4)	20 (26.3)	11 (14.5)	7 (9.2)	2 (2.6)	3 (3.9)	4 (5.3)	2 (2.6)	0 (0)	76
Pharyngeal	Female	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	0 (0)	3
Rectal	Male	2 (1.9)	17 (16.2)	26 (24.8)	23 (21.9)	16 (15.2)	6 (5.7)	8 (7.6)	4 (3.8)	1 (1.0)	1 (1.0)	1 (1.0)	105
Rectal	Female	0 (0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	2

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	10 (7.8)	0 (0)	0 (0)	23 (18.0)	78 (60.9)	0 (0)	17 (13.3)	128
Genital	Female	0 (0)	2 (33.3)	0 (0)	0 (0)	2 (33.3)	2 (33.3)	0 (0)	0 (0)	6
Pharyngeal	Male	0 (0)	18 (23.7)	0 (0)	0 (0)	12 (15.8)	40 (52.6)	0 (0)	6 (7.9)	76
Pharyngeal	Female	0 (0)	1 (33.3)	0 (0)	0 (0)	2 (66.7)	0 (0)	0 (0)	0 (0)	3
Rectal	Male	0 (0)	21 (20.0)	0 (0)	0 (0)	10 (9.5)	66 (62.9)	0 (0)	8 (7.6)	105
Rectal	Female	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	2

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	47	40	9	96
Genital	2022	72	44	13	129
Genital	2023	71	37	5	113
Pharyngeal	2021	32	4	5	41
Pharyngeal	2022	58	3	7	68
Pharyngeal	2023	56	5	3	64
Rectal	2021	59	0	2	61
Rectal	2022	93	3	4	100
Rectal	2023	84	0	2	86

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	113 (63.5)	51 (28.7)	8 (4.5)	6 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	178
Genital	2022	84 (64.6)	34 (26.2)	5 (3.8)	7 (5.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	130
Genital	2023	86 (62.3)	28 (20.3)	9 (6.5)	15 (10.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	138
Pharyngeal	2021	46 (59.0)	26 (33.3)	0 (0.0)	6 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	78
Pharyngeal	2022	39 (51.3)	25 (32.9)	3 (3.9)	9 (11.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	76
Pharyngeal	2023	48 (57.8)	25 (30.1)	8 (9.6)	2 (2.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	83
Rectal	2021	83 (58.0)	48 (33.6)	4 (2.8)	8 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	143
Rectal	2022	49 (44.1)	37 (33.3)	8 (7.2)	17 (15.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	111
Rectal	2023	69 (61.1)	25 (22.1)	10 (8.8)	9 (8.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	106 (59.6)	62 (34.8)	10 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	178
Genital	2022	79 (60.8)	42 (32.3)	9 (6.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	130
Genital	2023	83 (60.1)	43 (31.2)	12 (8.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	138
Pharyngeal	2021	42 (53.8)	29 (37.2)	7 (9.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	78
Pharyngeal	2022	43 (56.6)	30 (39.5)	3 (3.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	76
Pharyngeal	2023	43 (51.8)	34 (41.0)	6 (7.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	83
Rectal	2021	79 (55.2)	56 (39.2)	8 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	143
Rectal	2022	50 (45.0)	52 (46.8)	9 (8.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	111
Rectal	2023	65 (57.5)	40 (35.4)	8 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	113

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	13 (7.3)	130 (73.0)	11 (6.2)	17 (9.6)	6 (3.4)	1 (0.6)	0 (0.0)	0 (0.0)	178
Genital	2022	14 (10.8)	84 (64.6)	11 (8.5)	7 (5.4)	13 (10.0)	0 (0.0)	0 (0.0)	1 (0.8)	130
Genital	2023	21 (15.2)	70 (50.7)	21 (15.2)	12 (8.7)	13 (9.4)	0 (0.0)	0 (0.0)	1 (0.7)	138
Pharyngeal	2021	2 (2.6)	45 (57.7)	13 (16.7)	16 (20.5)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	78
Pharyngeal	2022	7 (9.2)	49 (64.5)	8 (10.5)	6 (7.9)	5 (6.6)	0 (0.0)	0 (0.0)	1 (1.3)	76
Pharyngeal	2023	5 (6.0)	49 (59.0)	7 (8.4)	13 (15.7)	8 (9.6)	0 (0.0)	0 (0.0)	1 (1.2)	83
Rectal	2021	5 (3.5)	83 (58.0)	17 (11.9)	26 (18.2)	12 (8.4)	0 (0.0)	0 (0.0)	0 (0.0)	143
Rectal	2022	12 (10.8)	66 (59.5)	7 (6.3)	15 (13.5)	11 (9.9)	0 (0.0)	0 (0.0)	0 (0.0)	111
Rectal	2023	8 (7.1)	69 (61.1)	16 (14.2)	8 (7.1)	11 (9.7)	0 (0.0)	0 (0.0)	1 (0.9)	113

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.



Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 47 (0.0)	0 / 40 (0.0)	0 / 9 (0.0)	0 / 96 (0.0)
Genital	2022	0 / 72 (0.0)	0 / 44 (0.0)	0 / 13 (0.0)	0 / 129 (0.0)
Genital	2023	0 / 71 (0.0)	0 / 37 (0.0)	0 / 5 (0.0)	0 / 113 (0.0)
Pharyngeal	2021	0 / 32 (0.0)	0 / 4 (0.0)	0 / 5 (0.0)	0 / 41 (0.0)
Pharyngeal	2022	0 / 58 (0.0)	0 / 3 (0.0)	0 / 7 (0.0)	0 / 68 (0.0)
Pharyngeal	2023	0 / 56 (0.0)	0 / 5 (0.0)	0 / 3 (0.0)	0 / 64 (0.0)
Rectal	2021	0 / 59 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 61 (0.0)
Rectal	2022	0 / 93 (0.0)	0 / 3 (0.0)	0 / 4 (0.0)	0 / 100 (0.0)
Rectal	2023	0 / 84 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 86 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 47 (0.0)	0 / 40 (0.0)	0 / 9 (0.0)	0 / 96 (0.0)
Genital	2022	0 / 72 (0.0)	0 / 44 (0.0)	0 / 13 (0.0)	0 / 129 (0.0)
Genital	2023	0 / 71 (0.0)	0 / 37 (0.0)	0 / 5 (0.0)	0 / 113 (0.0)
Pharyngeal	2021	0 / 32 (0.0)	0 / 4 (0.0)	0 / 5 (0.0)	0 / 41 (0.0)
Pharyngeal	2022	0 / 58 (0.0)	0 / 3 (0.0)	0 / 7 (0.0)	0 / 68 (0.0)
Pharyngeal	2023	0 / 56 (0.0)	0 / 5 (0.0)	0 / 3 (0.0)	0 / 64 (0.0)
Rectal	2021	0 / 59 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 61 (0.0)
Rectal	2022	0 / 93 (0.0)	0 / 3 (0.0)	0 / 4 (0.0)	0 / 100 (0.0)
Rectal	2023	0 / 84 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 86 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	3 / 47 (6.4)	1 / 40 (2.5)	1 / 9 (11.1)	5 / 96 (5.2)
Genital	2022	13 / 72 (18.1)	1 / 44 (2.3)	0 / 13 (0.0)	14 / 129 (10.9)
Genital	2023	9 / 71 (12.7)	1 / 37 (2.7)	0 / 5 (0.0)	10 / 113 (8.8)
Pharyngeal	2021	0 / 32 (0.0)	0 / 4 (0.0)	1 / 5 (20.0)	1 / 41 (2.4)
Pharyngeal	2022	6 / 58 (10.3)	0 / 3 (0.0)	0 / 7 (0.0)	6 / 68 (8.8)
Pharyngeal	2023	8 / 56 (14.3)	0 / 5 (0.0)	0 / 3 (0.0)	8 / 64 (12.5)
Rectal	2021	10 / 59 (16.9)	0 / 0 (0.0)	0 / 2 (0.0)	10 / 61 (16.4)
Rectal	2022	9 / 93 (9.7)	1 / 3 (33.3)	0 / 4 (0.0)	10 / 100 (10.0)
Rectal	2023	8 / 84 (9.5)	0 / 0 (0.0)	1 / 2 (50.0)	9 / 86 (10.5)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Orange County, California, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	14 / 47 (29.8)	10 / 40 (25.0)	3 / 9 (33.3)	27 / 96 (28.1)
Genital	2022	24 / 72 (33.3)	16 / 44 (36.4)	6 / 13 (46.2)	46 / 129 (35.7)
Genital	2023	36 / 71 (50.7)	16 / 37 (43.2)	5 / 5 (100.0)	57 / 113 (50.4)
Pharyngeal	2021	8 / 32 (25.0)	0 / 4 (0.0)	1 / 5 (20.0)	9 / 41 (22.0)
Pharyngeal	2022	22 / 58 (37.9)	3 / 3 (100.0)	2 / 7 (28.6)	27 / 68 (39.7)
Pharyngeal	2023	28 / 56 (50.0)	3 / 5 (60.0)	3 / 3 (100.0)	34 / 64 (53.1)
Rectal	2021	21 / 59 (35.6)	0 / 0 (0.0)	1 / 2 (50.0)	22 / 61 (36.1)
Rectal	2022	47 / 93 (50.5)	0 / 3 (0.0)	1 / 4 (25.0)	48 / 100 (48.0)
Rectal	2023	39 / 84 (46.4)	0 / 0 (0.0)	1 / 2 (50.0)	40 / 86 (46.5)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	20 (12.7)	39 (24.7)	31 (19.6)	26 (16.5)	20 (12.7)	9 (5.7)	2 (1.3)	4 (2.5)	1 (0.6)	4 (2.5)	2 (1.3)	158
Genital	Female	1 (20.0)	3 (60.0)	0 (0)	1 (20.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	5
Pharyngeal	Male	2 (14.3)	4 (28.6)	3 (21.4)	0 (0)	3 (21.4)	0 (0)	0 (0)	1 (7.1)	1 (7.1)	0 (0)	0 (0)	14
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	2 (5.9)	7 (20.6)	10 (29.4)	6 (17.6)	4 (11.8)	3 (8.8)	0 (0)	0 (0)	1 (2.9)	1 (2.9)	0 (0)	34
Rectal	Female	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	2 (1.3)	98 (62.0)	0 (0)	10 (6.3)	15 (9.5)	16 (10.1)	17 (10.8)	158
Genital	Female	0 (0)	1 (20.0)	2 (40.0)	0 (0)	1 (20.0)	1 (20.0)	0 (0)	0 (0)	5
Pharyngeal	Male	0 (0)	0 (0)	4 (28.6)	0 (0)	3 (21.4)	2 (14.3)	2 (14.3)	3 (21.4)	14
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	9 (26.5)	0 (0)	5 (14.7)	7 (20.6)	7 (20.6)	6 (17.6)	34
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	1

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	55	152	7	214
Genital	2022	76	177	5	258
Genital	2023	45	112	5	162
Pharyngeal	2021	3	1	1	5
Pharyngeal	2022	6	0	0	6
Pharyngeal	2023	14	0	0	14
Rectal	2021	17	0	0	17
Rectal	2022	34	0	0	34
Rectal	2023	33	0	1	34

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	182 (83.9)	28 (12.9)	4 (1.8)	3 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	217
Genital	2022	202 (77.1)	50 (19.1)	6 (2.3)	4 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	262
Genital	2023	106 (65.0)	37 (22.7)	11 (6.7)	8 (4.9)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	163
Pharyngeal	2021	4 (80.0)	0 (0.0)	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	5 (83.3)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2023	7 (50.0)	3 (21.4)	0 (0.0)	3 (21.4)	1 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2021	14 (77.8)	1 (5.6)	1 (5.6)	2 (11.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2022	24 (70.6)	5 (14.7)	3 (8.8)	1 (2.9)	0 (0.0)	0 (0.0)	1 (2.9)	0 (0.0)	34
Rectal	2023	22 (62.9)	5 (14.3)	3 (8.6)	4 (11.4)	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	35

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	169 (77.9)	42 (19.4)	6 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	217
Genital	2022	184 (70.2)	65 (24.8)	12 (4.6)	1 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	262
Genital	2023	101 (62.0)	47 (28.8)	14 (8.6)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	163
Pharyngeal	2021	3 (60.0)	1 (20.0)	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	6 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2023	7 (50.0)	3 (21.4)	4 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2021	11 (61.1)	5 (27.8)	1 (5.6)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2022	21 (61.8)	9 (26.5)	2 (5.9)	1 (2.9)	0 (0.0)	0 (0.0)	1 (2.9)	0 (0.0)	34
Rectal	2023	19 (54.3)	9 (25.7)	6 (17.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.9)	35

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	39 (18.0)	119 (54.8)	26 (12.0)	25 (11.5)	6 (2.8)	2 (0.9)	0 (0.0)	0 (0.0)	217
Genital	2022	85 (32.4)	102 (38.9)	35 (13.4)	32 (12.2)	7 (2.7)	0 (0.0)	1 (0.4)	0 (0.0)	262
Genital	2023	34 (20.9)	77 (47.2)	13 (8.0)	23 (14.1)	6 (3.7)	1 (0.6)	8 (4.9)	1 (0.6)	163
Pharyngeal	2021	1 (20.0)	2 (40.0)	0 (0.0)	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	0 (0.0)	3 (50.0)	2 (33.3)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	6
Pharyngeal	2023	2 (14.3)	7 (50.0)	3 (21.4)	0 (0.0)	2 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)	14
Rectal	2021	1 (5.6)	13 (72.2)	3 (16.7)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Rectal	2022	10 (29.4)	12 (35.3)	6 (17.6)	4 (11.8)	1 (2.9)	1 (2.9)	0 (0.0)	0 (0.0)	34
Rectal	2023	3 (8.6)	19 (54.3)	3 (8.6)	8 (22.9)	1 (2.9)	0 (0.0)	0 (0.0)	1 (2.9)	35

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.



Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 55 (0.0)	0 / 152 (0.0)	0 / 7 (0.0)	0 / 214 (0.0)
Genital	2022	0 / 76 (0.0)	0 / 177 (0.0)	0 / 5 (0.0)	0 / 258 (0.0)
Genital	2023	0 / 45 (0.0)	1 / 112 (0.9)	0 / 5 (0.0)	1 / 162 (0.6)
Pharyngeal	2021	0 / 3 (0.0)	0 / 1 (0.0)	0 / 1 (0.0)	0 / 5 (0.0)
Pharyngeal	2022	0 / 6 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 6 (0.0)
Pharyngeal	2023	1 / 14 (7.1)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 14 (7.1)
Rectal	2021	0 / 17 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 17 (0.0)
Rectal	2022	1 / 34 (2.9)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 34 (2.9)
Rectal	2023	1 / 33 (3.0)	0 / 0 (0.0)	0 / 1 (0.0)	1 / 34 (2.9)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 55 (0.0)	0 / 152 (0.0)	0 / 7 (0.0)	0 / 214 (0.0)
Genital	2022	0 / 76 (0.0)	0 / 177 (0.0)	0 / 5 (0.0)	0 / 258 (0.0)
Genital	2023	0 / 45 (0.0)	0 / 112 (0.0)	0 / 5 (0.0)	0 / 162 (0.0)
Pharyngeal	2021	0 / 3 (0.0)	0 / 1 (0.0)	0 / 1 (0.0)	0 / 5 (0.0)
Pharyngeal	2022	0 / 6 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 6 (0.0)
Pharyngeal	2023	0 / 14 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 14 (0.0)
Rectal	2021	0 / 17 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 17 (0.0)
Rectal	2022	1 / 34 (2.9)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 34 (2.9)
Rectal	2023	1 / 33 (3.0)	0 / 0 (0.0)	0 / 1 (0.0)	1 / 34 (2.9)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	3 / 55 (5.5)	5 / 152 (3.3)	0 / 7 (0.0)	8 / 214 (3.7)
Genital	2022	0 / 76 (0.0)	8 / 177 (4.5)	0 / 5 (0.0)	8 / 258 (3.1)
Genital	2023	2 / 45 (4.4)	13 / 112 (11.6)	1 / 5 (20.0)	16 / 162 (9.9)
Pharyngeal	2021	1 / 3 (33.3)	0 / 1 (0.0)	0 / 1 (0.0)	1 / 5 (20.0)
Pharyngeal	2022	0 / 6 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 6 (0.0)
Pharyngeal	2023	2 / 14 (14.3)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 14 (14.3)
Rectal	2021	0 / 17 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 17 (0.0)
Rectal	2022	2 / 34 (5.9)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 34 (5.9)
Rectal	2023	2 / 33 (6.1)	0 / 0 (0.0)	0 / 1 (0.0)	2 / 34 (5.9)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Philadelphia, Pennsylvania, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	21 / 55 (38.2)	70 / 152 (46.1)	2 / 7 (28.6)	93 / 214 (43.5)
Genital	2022	35 / 76 (46.1)	58 / 177 (32.8)	0 / 5 (0.0)	93 / 258 (36.0)
Genital	2023	25 / 45 (55.6)	43 / 112 (38.4)	3 / 5 (60.0)	71 / 162 (43.8)
Pharyngeal	2021	3 / 3 (100.0)	0 / 1 (0.0)	1 / 1 (100.0)	4 / 5 (80.0)
Pharyngeal	2022	3 / 6 (50.0)	0 / 0 (0.0)	0 / 0 (0.0)	3 / 6 (50.0)
Pharyngeal	2023	8 / 14 (57.1)	0 / 0 (0.0)	0 / 0 (0.0)	8 / 14 (57.1)
Rectal	2021	8 / 17 (47.1)	0 / 0 (0.0)	0 / 0 (0.0)	8 / 17 (47.1)
Rectal	2022	16 / 34 (47.1)	0 / 0 (0.0)	0 / 0 (0.0)	16 / 34 (47.1)
Rectal	2023	14 / 33 (42.4)	0 / 0 (0.0)	1 / 1 (100.0)	15 / 34 (44.1)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	14 (5.7)	52 (21.1)	48 (19.5)	58 (23.6)	26 (10.6)	21 (8.5)	12 (4.9)	4 (1.6)	8 (3.3)	1 (0.4)	2 (0.8)	246
Genital	Female	12 (26.1)	16 (34.8)	8 (17.4)	4 (8.7)	2 (4.3)	2 (4.3)	1 (2.2)	0 (0)	1 (2.2)	0 (0)	0 (0)	46
Pharyngeal	Male	2 (3.6)	17 (30.4)	8 (14.3)	16 (28.6)	5 (8.9)	3 (5.4)	2 (3.6)	0 (0)	3 (5.4)	0 (0)	0 (0)	56
Pharyngeal	Female	2 (10.5)	11 (57.9)	2 (10.5)	3 (15.8)	0 (0)	1 (5.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	19
Rectal	Male	4 (5.5)	18 (24.7)	18 (24.7)	13 (17.8)	9 (12.3)	1 (1.4)	5 (6.8)	2 (2.7)	2 (2.7)	1 (1.4)	0 (0)	73
Rectal	Female	0 (0)	1 (25.0)	2 (50.0)	0 (0)	0 (0)	1 (25.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	2 (0.8)	2 (0.8)	81 (32.9)	0 (0)	48 (19.5)	102 (41.5)	9 (3.7)	2 (0.8)	246
Genital	Female	1 (2.2)	0 (0)	4 (8.7)	0 (0)	11 (23.9)	29 (63.0)	0 (0)	1 (2.2)	46
Pharyngeal	Male	0 (0)	0 (0)	3 (5.4)	0 (0)	18 (32.1)	34 (60.7)	1 (1.8)	0 (0)	56
Pharyngeal	Female	1 (5.3)	0 (0)	1 (5.3)	0 (0)	5 (26.3)	12 (63.2)	0 (0)	0 (0)	19
Rectal	Male	3 (4.1)	3 (4.1)	1 (1.4)	0 (0)	19 (26.0)	45 (61.6)	2 (2.7)	0 (0)	73
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	2 (50.0)	2 (50.0)	0 (0)	0 (0)	4

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	76	204	44	324
Genital	2022	69	166	49	284
Genital	2023	91	155	46	292
Pharyngeal	2021	31	12	25	68
Pharyngeal	2022	45	19	34	98
Pharyngeal	2023	43	12	19	74
Rectal	2021	46	4	1	51
Rectal	2022	66	0	5	71
Rectal	2023	72	1	4	77

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	265 (81.8)	47 (14.5)	3 (0.9)	9 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	324
Genital	2022	197 (69.4)	72 (25.4)	7 (2.5)	6 (2.1)	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	284
Genital	2023	216 (74.0)	56 (19.2)	9 (3.1)	11 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	292
Pharyngeal	2021	49 (70.0)	14 (20.0)	1 (1.4)	5 (7.1)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	70
Pharyngeal	2022	73 (74.5)	21 (21.4)	2 (2.0)	2 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	98
Pharyngeal	2023	46 (61.3)	12 (16.0)	9 (12.0)	8 (10.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	75
Rectal	2021	41 (80.4)	8 (15.7)	1 (2.0)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	49 (69.0)	20 (28.2)	1 (1.4)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	71
Rectal	2023	48 (62.3)	16 (20.8)	3 (3.9)	8 (10.4)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	77

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	227 (70.1)	78 (24.1)	18 (5.6)	1 (0.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	324
Genital	2022	192 (67.6)	83 (29.2)	7 (2.5)	2 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	284
Genital	2023	194 (66.4)	77 (26.4)	18 (6.2)	3 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	292
Pharyngeal	2021	43 (61.4)	18 (25.7)	6 (8.6)	3 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	70
Pharyngeal	2022	62 (63.3)	30 (30.6)	6 (6.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	98
Pharyngeal	2023	35 (46.7)	24 (32.0)	14 (18.7)	2 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	75
Rectal	2021	33 (64.7)	14 (27.5)	4 (7.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	49 (69.0)	20 (28.2)	2 (2.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	71
Rectal	2023	42 (54.5)	25 (32.5)	5 (6.5)	5 (6.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	77

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	48 (14.8)	216 (66.7)	20 (6.2)	32 (9.9)	5 (1.5)	1 (0.3)	0 (0.0)	2 (0.6)	324
Genital	2022	59 (20.8)	164 (57.7)	15 (5.3)	36 (12.7)	8 (2.8)	0 (0.0)	1 (0.4)	1 (0.4)	284
Genital	2023	39 (13.4)	158 (54.1)	29 (9.9)	47 (16.1)	16 (5.5)	0 (0.0)	0 (0.0)	3 (1.0)	292
Pharyngeal	2021	10 (14.3)	37 (52.9)	8 (11.4)	12 (17.1)	3 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)	70
Pharyngeal	2022	20 (20.4)	52 (53.1)	6 (6.1)	12 (12.2)	4 (4.1)	1 (1.0)	2 (2.0)	1 (1.0)	98
Pharyngeal	2023	5 (6.7)	40 (53.3)	6 (8.0)	15 (20.0)	7 (9.3)	0 (0.0)	0 (0.0)	2 (2.7)	75
Rectal	2021	4 (7.8)	33 (64.7)	4 (7.8)	9 (17.6)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Rectal	2022	7 (9.9)	44 (62.0)	2 (2.8)	15 (21.1)	3 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	71
Rectal	2023	7 (9.1)	49 (63.6)	8 (10.4)	9 (11.7)	4 (5.2)	0 (0.0)	0 (0.0)	0 (0.0)	77

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.



Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 76 (0.0)	0 / 204 (0.0)	0 / 44 (0.0)	0 / 324 (0.0)
Genital	2022	0 / 69 (0.0)	2 / 166 (1.2)	0 / 49 (0.0)	2 / 284 (0.7)
Genital	2023	0 / 91 (0.0)	0 / 155 (0.0)	0 / 46 (0.0)	0 / 292 (0.0)
Pharyngeal	2021	0 / 31 (0.0)	0 / 12 (0.0)	1 / 25 (4.0)	1 / 68 (1.5)
Pharyngeal	2022	0 / 45 (0.0)	0 / 19 (0.0)	0 / 34 (0.0)	0 / 98 (0.0)
Pharyngeal	2023	0 / 43 (0.0)	0 / 12 (0.0)	0 / 19 (0.0)	0 / 74 (0.0)
Rectal	2021	0 / 46 (0.0)	0 / 4 (0.0)	0 / 1 (0.0)	0 / 51 (0.0)
Rectal	2022	0 / 66 (0.0)	0 / 0 (0.0)	0 / 5 (0.0)	0 / 71 (0.0)
Rectal	2023	2 / 72 (2.8)	0 / 1 (0.0)	0 / 4 (0.0)	2 / 77 (2.6)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 76 (0.0)	0 / 204 (0.0)	0 / 44 (0.0)	0 / 324 (0.0)
Genital	2022	0 / 69 (0.0)	0 / 166 (0.0)	0 / 49 (0.0)	0 / 284 (0.0)
Genital	2023	0 / 91 (0.0)	0 / 155 (0.0)	0 / 46 (0.0)	0 / 292 (0.0)
Pharyngeal	2021	0 / 31 (0.0)	0 / 12 (0.0)	0 / 25 (0.0)	0 / 68 (0.0)
Pharyngeal	2022	0 / 45 (0.0)	0 / 19 (0.0)	0 / 34 (0.0)	0 / 98 (0.0)
Pharyngeal	2023	0 / 43 (0.0)	0 / 12 (0.0)	0 / 19 (0.0)	0 / 74 (0.0)
Rectal	2021	0 / 46 (0.0)	0 / 4 (0.0)	0 / 1 (0.0)	0 / 51 (0.0)
Rectal	2022	0 / 66 (0.0)	0 / 0 (0.0)	0 / 5 (0.0)	0 / 71 (0.0)
Rectal	2023	0 / 72 (0.0)	0 / 1 (0.0)	0 / 4 (0.0)	0 / 77 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	3 / 76 (3.9)	4 / 204 (2.0)	1 / 44 (2.3)	8 / 324 (2.5)
Genital	2022	3 / 69 (4.3)	5 / 166 (3.0)	2 / 49 (4.1)	10 / 284 (3.5)
Genital	2023	5 / 91 (5.5)	10 / 155 (6.5)	4 / 46 (8.7)	19 / 292 (6.5)
Pharyngeal	2021	0 / 31 (0.0)	0 / 12 (0.0)	3 / 25 (12.0)	3 / 68 (4.4)
Pharyngeal	2022	2 / 45 (4.4)	2 / 19 (10.5)	4 / 34 (11.8)	8 / 98 (8.2)
Pharyngeal	2023	4 / 43 (9.3)	4 / 12 (33.3)	1 / 19 (5.3)	9 / 74 (12.2)
Rectal	2021	1 / 46 (2.2)	0 / 4 (0.0)	0 / 1 (0.0)	1 / 51 (2.0)
Rectal	2022	2 / 66 (3.0)	0 / 0 (0.0)	1 / 5 (20.0)	3 / 71 (4.2)
Rectal	2023	3 / 72 (4.2)	0 / 1 (0.0)	1 / 4 (25.0)	4 / 77 (5.2)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Phoenix, Arizona, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	27 / 76 (35.5)	65 / 204 (31.9)	14 / 44 (31.8)	106 / 324 (32.7)
Genital	2022	26 / 69 (37.7)	38 / 166 (22.9)	15 / 49 (30.6)	79 / 284 (27.8)
Genital	2023	36 / 91 (39.6)	46 / 155 (29.7)	13 / 46 (28.3)	95 / 292 (32.5)
Pharyngeal	2021	12 / 31 (38.7)	3 / 12 (25.0)	3 / 25 (12.0)	18 / 68 (26.5)
Pharyngeal	2022	19 / 45 (42.2)	10 / 19 (52.6)	8 / 34 (23.5)	37 / 98 (37.8)
Pharyngeal	2023	24 / 43 (55.8)	5 / 12 (41.7)	7 / 19 (36.8)	36 / 74 (48.6)
Rectal	2021	26 / 46 (56.5)	3 / 4 (75.0)	0 / 1 (0.0)	29 / 51 (56.9)
Rectal	2022	25 / 66 (37.9)	0 / 0 (0.0)	1 / 5 (20.0)	26 / 71 (36.6)
Rectal	2023	34 / 72 (47.2)	0 / 1 (0.0)	2 / 4 (50.0)	36 / 77 (46.8)

MSM = Men who have sex with men; MSW = Men who have sex with women only.  
Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

**Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2023**

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	4 (9.3)	7 (16.3)	12 (27.9)	10 (23.3)	1 (2.3)	5 (11.6)	0 (0)	3 (7.0)	0 (0)	1 (2.3)	0 (0)	43
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.

**Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2023**

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	0 (0)	36 (83.7)	0 (0)	3 (7.0)	1 (2.3)	1 (2.3)	2 (4.7)	43
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	7	32	0	39
Genital	2022	20	29	0	49
Genital	2023	12	30	0	42
Pharyngeal	2021	3	1	0	4
Pharyngeal	2022	2	0	0	2
Pharyngeal	2023	0	0	0	0
Rectal	2021	9	0	2	11
Rectal	2022	7	0	0	7
Rectal	2023	0	0	0	0

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	26 (66.7)	7 (17.9)	2 (5.1)	4 (10.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	39
Genital	2022	41 (80.4)	5 (9.8)	3 (5.9)	2 (3.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Genital	2023	30 (69.8)	4 (9.3)	2 (4.7)	7 (16.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	43
Pharyngeal	2021	2 (40.0)	1 (20.0)	0 (0.0)	2 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	2 (66.7)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	6 (54.5)	2 (18.2)	0 (0.0)	3 (27.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	5 (71.4)	2 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	29 (74.4)	7 (17.9)	3 (7.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	39
Genital	2022	42 (82.4)	6 (11.8)	2 (3.9)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Genital	2023	23 (53.5)	13 (30.2)	6 (14.0)	1 (2.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	43
Pharyngeal	2021	3 (60.0)	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	4 (36.4)	6 (54.5)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	5 (71.4)	2 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	7
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	6 (15.4)	26 (66.7)	2 (5.1)	3 (7.7)	1 (2.6)	1 (2.6)	0 (0.0)	0 (0.0)	39
Genital	2022	8 (15.7)	26 (51.0)	9 (17.6)	7 (13.7)	1 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	51
Genital	2023	7 (16.3)	25 (58.1)	4 (9.3)	5 (11.6)	2 (4.7)	0 (0.0)	0 (0.0)	0 (0.0)	43
Pharyngeal	2021	1 (20.0)	3 (60.0)	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5
Pharyngeal	2022	1 (33.3)	1 (33.3)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Pharyngeal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0
Rectal	2021	1 (9.1)	8 (72.7)	1 (9.1)	1 (9.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	11
Rectal	2022	2 (28.6)	3 (42.9)	0 (0.0)	0 (0.0)	2 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)	7
Rectal	2023	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.



Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 7 (0.0)	0 / 32 (0.0)	0 / 0 (0.0)	0 / 39 (0.0)
Genital	2022	0 / 20 (0.0)	0 / 29 (0.0)	0 / 0 (0.0)	0 / 49 (0.0)
Genital	2023	0 / 12 (0.0)	0 / 30 (0.0)	0 / 0 (0.0)	0 / 42 (0.0)
Pharyngeal	2021	0 / 3 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2022	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	0 / 9 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 11 (0.0)
Rectal	2022	0 / 7 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 7 (0.0)
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Where blanks exist on the graphs for years of participation, no data were available for the criteria presented.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 7 (0.0)	0 / 32 (0.0)	0 / 0 (0.0)	0 / 39 (0.0)
Genital	2022	0 / 20 (0.0)	0 / 29 (0.0)	0 / 0 (0.0)	0 / 49 (0.0)
Genital	2023	0 / 12 (0.0)	0 / 30 (0.0)	0 / 0 (0.0)	0 / 42 (0.0)
Pharyngeal	2021	0 / 3 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2022	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	0 / 9 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 11 (0.0)
Rectal	2022	0 / 7 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 7 (0.0)
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 7 (0.0)	2 / 32 (6.3)	0 / 0 (0.0)	2 / 39 (5.1)
Genital	2022	0 / 20 (0.0)	1 / 29 (3.4)	0 / 0 (0.0)	1 / 49 (2.0)
Genital	2023	1 / 12 (8.3)	1 / 30 (3.3)	0 / 0 (0.0)	2 / 42 (4.8)
Pharyngeal	2021	0 / 3 (0.0)	0 / 1 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2022	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	0 / 9 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)	0 / 11 (0.0)
Rectal	2022	2 / 7 (28.6)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 7 (28.6)
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), Pontiac, Michigan, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	4 / 7 (57.1)	10 / 32 (31.3)	0 / 0 (0.0)	14 / 39 (35.9)
Genital	2022	5 / 20 (25.0)	7 / 29 (24.1)	0 / 0 (0.0)	12 / 49 (24.5)
Genital	2023	7 / 12 (58.3)	9 / 30 (30.0)	0 / 0 (0.0)	16 / 42 (38.1)
Pharyngeal	2021	1 / 3 (33.3)	0 / 1 (0.0)	0 / 0 (0.0)	1 / 4 (25.0)
Pharyngeal	2022	1 / 2 (50.0)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 2 (50.0)
Pharyngeal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)
Rectal	2021	4 / 9 (44.4)	0 / 0 (0.0)	1 / 2 (50.0)	5 / 11 (45.5)
Rectal	2022	1 / 7 (14.3)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 7 (14.3)
Rectal	2023	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table A. Percentage of Participants by Sex, Age Group, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2023

Site of Infection	Patient Sex	<20 n (%)	20-24 n (%)	25-29 n (%)	30-34 n (%)	35-39 n (%)	40-44 n (%)	45-49 n (%)	50-54 n (%)	55-59 n (%)	60-64 n (%)	65+ n (%)	Total
Genital	Male	0 (0)	2 (9.5)	4 (19.0)	2 (9.5)	11 (52.4)	0 (0)	0 (0)	0 (0)	2 (9.5)	0 (0)	0 (0)	21
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	1 (50.0)	1 (50.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2
Pharyngeal	Female	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	0 (0)	2
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases with unknown age were excluded.

Table B. Percentage of Participants by Sex, Race/Ethnicity, and Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2023

Site of Infection	Patient Sex	AI/AN n (%)	Asian n (%)	Black n (%)	NHOPI n (%)	White n (%)	Hispanic n (%)	Multiracial n (%)	Other/Unknown n (%)	Total
Genital	Male	0 (0)	2 (9.5)	7 (33.3)	0 (0)	4 (19.0)	8 (38.1)	0 (0)	0 (0)	21
Genital	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0
Pharyngeal	Male	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	1 (50.0)	0 (0)	0 (0)	2
Pharyngeal	Female	0 (0)	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	0 (0)	0 (0)	1
Rectal	Male	0 (0)	0 (0)	0 (0)	0 (0)	1 (50.0)	1 (50.0)	0 (0)	0 (0)	2
Rectal	Female	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0

Cases are reported using Office of Management and Budget (OMB) compliant race and ethnicity categories.  
AI/AN = American Indian or Alaska Native; NHOPI = Native Hawaiian or Other Pacific Islander.

Table C. Number of *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2021-2023

Site of Infection	Year	MSM	MSW	Women	Total
Genital	2021	84	46	4	134
Genital	2022	7	11	0	18
Genital	2023	15	6	0	21
Pharyngeal	2021	26	0	4	30
Pharyngeal	2022	4	0	0	4
Pharyngeal	2023	2	0	1	3
Rectal	2021	29	0	1	30
Rectal	2022	3	0	0	3
Rectal	2023	2	0	0	2

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Table D. Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2021-2023

Site of Infection	Year	≤0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	Total
Genital	2021	87 (64.4)	39 (28.9)	7 (5.2)	2 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	135
Genital	2022	14 (77.8)	4 (22.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Genital	2023	13 (61.9)	2 (9.5)	4 (19.0)	1 (4.8)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	21
Pharyngeal	2021	18 (60.0)	11 (36.7)	0 (0.0)	1 (3.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30
Pharyngeal	2022	1 (25.0)	1 (25.0)	0 (0.0)	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	2023	1 (33.3)	0 (0.0)	0 (0.0)	1 (33.3)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2021	18 (58.1)	9 (29.0)	1 (3.2)	3 (9.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	31
Rectal	2022	2 (66.7)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2023	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value = cefixime MIC ≥0.25 µg/mL; CLSI Non-susceptible = cefixime MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a cefixime resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table E. Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2021-2023

Site of Infection	Year	≤0.008 n (%)	0.015 n (%)	0.03 n (%)	0.06 n (%)	0.125 n (%)	0.25 n (%)	0.5 n (%)	1.0 n (%)	Total
Genital	2021	77 (57.0)	51 (37.8)	7 (5.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	135
Genital	2022	11 (61.1)	7 (38.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	18
Genital	2023	11 (52.4)	7 (33.3)	2 (9.5)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	21
Pharyngeal	2021	18 (60.0)	10 (33.3)	2 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	30
Pharyngeal	2022	1 (25.0)	2 (50.0)	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	2023	1 (33.3)	1 (33.3)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2021	18 (58.1)	9 (29.0)	4 (12.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	31
Rectal	2022	2 (66.7)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2023	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value = ceftriaxone MIC ≥0.125 µg/mL; CLSI Non-susceptible = ceftriaxone MIC ≥0.5 µg/mL.

CLSI = Clinical & Laboratory Standards Institute.

Non-susceptible = Category used for isolates when only a susceptible breakpoint has been designated and the MIC is above the susceptible breakpoint.

As of publication, the CLSI has not established a ceftriaxone resistance breakpoint for *N. gonorrhoeae*.

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table F. Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) Among *Neisseria gonorrhoeae* Isolates by Anatomic Site of Infection, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2021-2023

Site of Infection	Year	≤0.06 n (%)	0.125-0.25 n (%)	0.5 n (%)	1.0 n (%)	2.0 n (%)	4.0 n (%)	8.0 n (%)	≥16.0 n (%)	Total
Genital	2021	12 (8.9)	90 (66.7)	7 (5.2)	13 (9.6)	13 (9.6)	0 (0.0)	0 (0.0)	0 (0.0)	135
Genital	2022	5 (27.8)	11 (61.1)	1 (5.6)	0 (0.0)	1 (5.6)	0 (0.0)	0 (0.0)	0 (0.0)	18
Genital	2023	2 (9.5)	9 (42.9)	3 (14.3)	6 (28.6)	1 (4.8)	0 (0.0)	0 (0.0)	0 (0.0)	21
Pharyngeal	2021	4 (13.3)	18 (60.0)	1 (3.3)	5 (16.7)	2 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)	30
Pharyngeal	2022	1 (25.0)	3 (75.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4
Pharyngeal	2023	0 (0.0)	0 (0.0)	1 (33.3)	1 (33.3)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2021	0 (0.0)	23 (74.2)	2 (6.5)	2 (6.5)	4 (12.9)	0 (0.0)	0 (0.0)	0 (0.0)	31
Rectal	2022	0 (0.0)	2 (66.7)	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	3
Rectal	2023	0 (0.0)	2 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2

GISP Alert Value: azithromycin MIC ≥2.0 µg/mL; FDA-STIC Resistant = azithromycin MIC ≥2.0 µg/mL.

FDA-STIC = FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria.

In 2025, azithromycin resistance was established as ≥2.0 µg/mL (FDA-STIC).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.



Table G. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Cefixime, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 84 (0.0)	0 / 46 (0.0)	0 / 4 (0.0)	0 / 134 (0.0)
Genital	2022	0 / 7 (0.0)	0 / 11 (0.0)	0 / 0 (0.0)	0 / 18 (0.0)
Genital	2023	0 / 15 (0.0)	1 / 6 (16.7)	0 / 0 (0.0)	1 / 21 (4.8)
Pharyngeal	2021	0 / 26 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)	0 / 30 (0.0)
Pharyngeal	2022	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	1 / 1 (100.0)	1 / 3 (33.3)
Rectal	2021	0 / 29 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 30 (0.0)
Rectal	2022	0 / 3 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 3 (0.0)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Cefixime elevated MIC  $\geq 0.25$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table H. Percentage of *Neisseria gonorrhoeae* Isolates with an Elevated Minimum Inhibitory Concentration (MIC) to Ceftriaxone, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	0 / 84 (0.0)	0 / 46 (0.0)	0 / 4 (0.0)	0 / 134 (0.0)
Genital	2022	0 / 7 (0.0)	0 / 11 (0.0)	0 / 0 (0.0)	0 / 18 (0.0)
Genital	2023	0 / 15 (0.0)	0 / 6 (0.0)	0 / 0 (0.0)	0 / 21 (0.0)
Pharyngeal	2021	0 / 26 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)	0 / 30 (0.0)
Pharyngeal	2022	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 3 (0.0)
Rectal	2021	0 / 29 (0.0)	0 / 0 (0.0)	0 / 1 (0.0)	0 / 30 (0.0)
Rectal	2022	0 / 3 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 3 (0.0)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ceftriaxone elevated MIC  $\geq 0.125$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table I. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Azithromycin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	7 / 84 (8.3)	4 / 46 (8.7)	1 / 4 (25.0)	12 / 134 (9.0)
Genital	2022	0 / 7 (0.0)	1 / 11 (9.1)	0 / 0 (0.0)	1 / 18 (5.6)
Genital	2023	1 / 15 (6.7)	0 / 6 (0.0)	0 / 0 (0.0)	1 / 21 (4.8)
Pharyngeal	2021	2 / 26 (7.7)	0 / 0 (0.0)	0 / 4 (0.0)	2 / 30 (6.7)
Pharyngeal	2022	0 / 4 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 4 (0.0)
Pharyngeal	2023	0 / 2 (0.0)	0 / 0 (0.0)	1 / 1 (100.0)	1 / 3 (33.3)
Rectal	2021	4 / 29 (13.8)	0 / 0 (0.0)	0 / 1 (0.0)	4 / 30 (13.3)
Rectal	2022	1 / 3 (33.3)	0 / 0 (0.0)	0 / 0 (0.0)	1 / 3 (33.3)
Rectal	2023	0 / 2 (0.0)	0 / 0 (0.0)	0 / 0 (0.0)	0 / 2 (0.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Azithromycin resistance  $\geq 2.0$   $\mu\text{g/mL}$ . (In 2025, FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria established azithromycin resistance as  $\geq 2.0$   $\mu\text{g/mL}$ ).

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.

Table J. Percentage of *Neisseria gonorrhoeae* Isolates with Resistance to Ciprofloxacin, by Anatomic Site of Infection and by Sex and Sex of Sex Partners, Enhanced Gonococcal Isolate Surveillance Project (eGISP), San Diego, California, 2021-2023

Site of Infection	Year	MSM n (%)	MSW n (%)	Women n (%)	Total n (%)
Genital	2021	38 / 84 (45.2)	19 / 46 (41.3)	0 / 4 (0.0)	57 / 134 (42.5)
Genital	2022	5 / 7 (71.4)	7 / 11 (63.6)	0 / 0 (0.0)	12 / 18 (66.7)
Genital	2023	9 / 15 (60.0)	3 / 6 (50.0)	0 / 0 (0.0)	12 / 21 (57.1)
Pharyngeal	2021	15 / 26 (57.7)	0 / 0 (0.0)	0 / 4 (0.0)	15 / 30 (50.0)
Pharyngeal	2022	3 / 4 (75.0)	0 / 0 (0.0)	0 / 0 (0.0)	3 / 4 (75.0)
Pharyngeal	2023	1 / 2 (50.0)	0 / 0 (0.0)	1 / 1 (100.0)	2 / 3 (66.7)
Rectal	2021	12 / 29 (41.4)	0 / 0 (0.0)	0 / 1 (0.0)	12 / 30 (40.0)
Rectal	2022	2 / 3 (66.7)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 3 (66.7)
Rectal	2023	2 / 2 (100.0)	0 / 0 (0.0)	0 / 0 (0.0)	2 / 2 (100.0)

MSM = Men who have sex with men; MSW = Men who have sex with women only.

Ciprofloxacin resistance MIC  $\geq 1.0$   $\mu\text{g/mL}$ .

Data for years 2020-2022 may not match previously reported data due to MIC data updates made by reporting labs.